If you are still having problems viewing this message, please click here for additional help.

Nature Medicine

Read the latest science news from A*STAR, the Agency for Science, Technology and Research, Singapore's leading research organization Recent stories:

Infectious diseases: Doubling down on infection 

Glaucoma: A bird's eye view for improved diagnosis 

Immunology: Newly identified cells in liver protection role 

July 2018 Volume 24, Issue 7

News Feature
Research Highlights
News & Views
Review Articles
Brief Communications
nature.com webcasts

Nature Research
Custom Media presents a webcast on: Combining scRNA-seq and Flow Analyses
Date: Tuesday, July 24, 2018
Join our webcast to learn how fluorescence intensity information from flow parameters can be merged into a single-cell RNA expression matrix and analysed.
This webcast has been produced on behalf of the sponsor who retains sole responsibility for content
Sponsored by: SeqGeq 


Harrington drug discovery research grants - awards up to $700,000

Harrington Discovery Institute at University Hospitals in Cleveland, Ohio invites Full Applications for the 2019 Harrington Scholar-Innovator Award, offering physician-scientists the resources to advance discoveries into medicines. Full Applications are accepted through May 10, 2018. Apply now at HarringtonDiscovery.org/Grant.
Nature Milestone: Anticoagulants from Nature Reviews Cardiology 

This Milestone plots the history of anticoagulant drugs, used to prevent and treat thrombotic disorders in millions of patients worldwide. Fourteen Milestone articles are presented on an interactive timeline with associated multimedia. 

Access free online >> 

Produced with support from: 
Portola Pharmaceuticals, Inc. 

Nature Outlook: Bladder cancer 

After three decades without progress, there is now hope that we can move the needle on treating bladder cancer. 

Access the free Outlook >> 

Produced with support from: 



Actionable equality    p881

News Feature


Matching up    pp882 - 884
Shraddha Chakradhar

Homeward bound    pp885 - 889
Shraddha Chakradhar

Animation on CRISPR: Gene editing and beyond

The CRISPR-Cas9 system has revolutionised gene editing, but cutting DNA isn't all it can do.

This Animation, from Nature Methods, explores where CRISPR might be headed next. 

Watch the Animation >> 

Produced with support from: 



F508del-CFTR is not corrected by thymosin α1    pp890 - 891
Elizabeth Matthes, John W. Hanrahan & André M. Cantin

Reply to ‘F508del-CFTR is not corrected by thymosin α1’    pp891 - 893
Luigina Romani, Claudia Stincardini, Stefano Giovagnoli, Maurizio Paci, Valeria R. Villella et al.

Nature Outlook: The future of medicine 

Modern medicine is affording people longer and healthier lives. But researchers want to take improvements in health even further. With advances in gene editing, technology to overcome paralysis and efforts to address high drug costs, the future of medicine is bright. 

Get your free access >> 

Produced with support from Merck KGaA, Darmstadt, Germany 



Searching for Alzheimer’s disease therapies    pp894 - 897
Hannah Stower

Research Highlights


A pig model of Huntington’s disease    p898
Hannah Stower

Detecting dengue    p898
Hannah Stower

Understanding genetic disease with electronic medical records    p898
Hannah Stower

Green light for data sharing    p898
Hannah Stower

Predicting colon cancer recurrence    p898
Hannah Stower

JOBS of the week
Postdoctoral research fellowship in Chemical Neuroscience
University of Oslo
Postdoctoral Fellow Position
Vanderbilt University Medical Center
Postdoctoral Research Fellow
Hospital for Special Surgery and Weill Cornell Medical College
Postdoctoral Research Associate
Texas A&M Institute of Biosciences and Technology
Postdoctoral Fellow- Immunology
NYU Langone Health
More Science jobs from
Cardiovascular, Allergy, and Respiratory Summit (CARPS)
San Diego, USA
More science events from

News & Views


A path to efficient gene editing    pp899 - 900
Fyodor D. Urnov

Fire prevention in the Parkinson’s disease brain    pp900 - 902
Lena Brundin, Liza Bergkvist & Patrik Brundin

A treatment strategy for KRAS-driven tumors    pp902 - 904
Trang T. Mai & Piro Lito

Predicting progression to AML    pp904 - 906
Rob S. Sellar, Siddhartha Jaiswal & Benjamin L. Ebert

Microbiome metabolomics reveals new drivers of human liver steatosis    pp906 - 907
Nathalie M. Delzenne & Laure B. Bindels

Review Articles


Mechanisms of NAFLD development and therapeutic strategies    pp908 - 922
Scott L. Friedman, Brent A. Neuschwander-Tetri, Mary Rinella & Arun J. Sanyal

Understanding of pathogenic mechanisms and clinical features of NAFLD is driving progress in therapeutic strategies now in clinical trials.


Brief Communications


Rapid HIV RNA rebound after antiretroviral treatment interruption in persons durably suppressed in Fiebig I acute HIV infection    pp923 - 926
Donn J. Colby, Lydie Trautmann, Suteeraporn Pinyakorn, Louise Leyre, Amélie Pagliuzza et al.

Initiation of antiretroviral therapy in the first 2 weeks of HIV infection fails to prevent resurgence of virus after stopping treatment, indicating early establishment of a resilient viral reservoir.


CRISPR–Cas9 genome editing induces a p53-mediated DNA damage response    pp927 - 930


CRISPR–Cas9-induced DNA damage triggers p53 to limit the efficiency of gene editing in immortalized human retinal pigment epithelial cells.




Block of A1 astrocyte conversion by microglia is neuroprotective in models of Parkinson’s disease    pp931 - 938
Seung Pil Yun, Tae-In Kam, Nikhil Panicker, SangMin Kim, Yumin Oh et al.

Agonism of microglial glucagon-like peptide-1 receptor (GLP1R) using a brain-penetrant peptide prevents the generation of neurotoxic astrocytes and ameliorates disease progression in two rodent models of Parkinson’s disease.


p53 inhibits CRISPR–Cas9 engineering in human pluripotent stem cells    pp939 - 946
Robert J. Ihry, Kathleen A. Worringer, Max R. Salick, Elizabeth Frias, Daniel Ho et al.

CRISPR–Cas9-induced DNA damage triggers p53 to limit the efficiency of gene editing in human pluripotent cells.


DNA repair processes are critical mediators of p53-dependent tumor suppression    pp947 - 953
Ana Janic, Liz J. Valente, Matthew J. Wakefield, Leon Di Stefano, Liz Milla et al.

In vivo shRNA screens in sensitized genetic backgrounds identify p53-activated target genes involved in DNA repair that enable its tumor suppressor function.


Mutant KRAS-driven cancers depend on PTPN11/SHP2 phosphatase    pp954 - 960
Dietrich A. Ruess, Guus J. Heynen, Katrin J. Ciecielski, Jiaoyu Ai, Alexandra Berninger et al.

The phosphatase SHP2 is required for mutant KRAS signaling in pancreatic and non-small-cell lung cancers and drives resistance to MEK inhibition.


SHP2 is required for growth of KRAS-mutant non-small-cell lung cancer in vivo    pp961 - 967
Sara Mainardi, Antonio Mulero-Sánchez, Anirudh Prahallad, Giovanni Germano, Astrid Bosma et al.

Combined inhibition of SHP2 and MEK is an effective therapeutic approach in non-small-cell lung cancer.


Targeting wild-type KRAS-amplified gastroesophageal cancer through combined MEK and SHP2 inhibition    pp968 - 977
Gabrielle S. Wong, Jin Zhou, Jie Bin Liu, Zhong Wu, Xinsen Xu et al.

Amplification of wild-type KRAS in a subset of gastroesophageal tumors drives intrinsic resistance to MAPK inhibition that can be overcome by combined targeting of MEK and SHP2.


Global characterization of T cells in non-small-cell lung cancer by single-cell sequencing    pp978 - 985
Xinyi Guo, Yuanyuan Zhang, Liangtao Zheng, Chunhong Zheng, Jintao Song et al.

Deep single-cell RNA sequencing of tumor-infiltrating T cells in non-small-cell lung cancer identifies features associated with functional states and clinical outcome


Single-cell profiling of breast cancer T cells reveals a tissue-resident memory subset associated with improved prognosis    pp986 - 993
Peter Savas, Balaji Virassamy, Chengzhong Ye, Agus Salim, Christopher P. Mintoff et al.

Extensive, high-dimensional characterization of T cells in breast cancer reveals activated TRM population and a gene signature associated with improved prognosis.




A transcriptionally and functionally distinct PD-1+ CD8+ T cell pool with predictive potential in non-small-cell lung cancer treated with PD-1 blockade    pp994 - 1004
Daniela S. Thommen, Viktor H. Koelzer, Petra Herzig, Andreas Roller, Marcel Trefny et al.

Tumor-infiltrating CD8+ T cells with high expression of PD-1 in non-small-cell lung cancer are distinct from exhausted T cells in chronic virus infection, have high tumor reactivity and associate with response to PD-1-targeted immunotherapy.


A human anti-IL-2 antibody that potentiates regulatory T cells by a structure-based mechanism    pp1005 - 1014
Eleonora Trotta, Paul H. Bessette, Stephanie L. Silveria, Lauren K. Ely, Kevin M. Jude et al.

A human anti-IL-2 antibody that selectively expands regulatory T cells is developed in this study for clinical applications aiming to mitigate autoimmune and inflammatory disorders and to promote transplant tolerance.


Somatic mutations precede acute myeloid leukemia years before diagnosis    pp1015 - 1023
Pinkal Desai, Nuria Mencia-Trinchant, Oleksandr Savenkov, Michael S. Simon, Gloria Cheang et al.

Somatic mutations detected years before diagnosis increase the odds of development of acute myeloid leukemia in women.


STAT3 labels a subpopulation of reactive astrocytes required for brain metastasis    pp1024 - 1035
Neibla Priego, Lucía Zhu, Cátia Monteiro, Manon Mulders, David Wasilewski et al.

Reactive astrocytes expressing STAT3 support the metastatic growth of tumor cells colonizing the brain and can be pharmacologically targeted to improve the clinical management of patients with secondary brain tumors.


An inhibitor of oxidative phosphorylation exploits cancer vulnerability    pp1036 - 1046
Jennifer R. Molina, Yuting Sun, Marina Protopopova, Sonal Gera, Madhavi Bandi et al.

A new inhibitor targeting the mitochondrial complex I shows antitumor activity in preclinical models of acute myeloid leukemia and glioblastoma relying on oxidative phosphorylation.


Mutations in the SWI/SNF complex induce a targetable dependence on oxidative phosphorylation in lung cancer    pp1047 - 1057
Yonathan Lissanu Deribe, Yuting Sun, Christopher Terranova, Fatima Khan, Juan Martinez-Ledesma et al.

SMARCA4 loss in non-small-cell lung cancer creates a metabolic dependency on oxidative phosphorylation that can be targeted using a new small-molecule inhibitor.


Inactivating hepatic follistatin alleviates hyperglycemia    pp1058 - 1069
Rongya Tao, Caixia Wang, Oliver Stöhr, Wei Qiu, Yue Hu et al.

Follistatin acts as a hepatokine to induce insulin resistance and can be targeted to improve diabetes in mice.


Molecular phenomics and metagenomics of hepatic steatosis in non-diabetic obese women    pp1070 - 1080
Lesley Hoyles, José-Manuel Fernández-Real, Massimo Federici, Matteo Serino, James Abbott et al.

Metabolic activity of specific human gut microorganisms contributes to liver steatosis in obese women.


Focal Point on Japan's Designated National University Initiative

Japan's radical new program to boost just a handful of universities has precedents across the world 

Access free online
nature events
Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here.
Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com
More Nature Events

You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount
(You will need to log in to be recognised as a nature.com registrant)

For further technical assistance, please contact our registration department

For print subscription enquiries, please contact our subscription department

For other enquiries, please contact our customer feedback department

Springer Nature | One New York Plaza, Suite 4500 | New York | NY 10004-1562 | USA

Springer Nature's worldwide offices:
London - Paris - Munich - New Delhi - Tokyo - Melbourne
San Diego - San Francisco - Washington - New York - Boston

Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at The Campus, 4 Crinan Street, London, N1 9XW.

© 2018 Macmillan Publishers Limited, part of Springer Nature. All Rights Reserved.

Springer Nature